3Kurzrock R, Kantarjian HM, Druker BJ, et al. Philadelphia chromosome-positive leukemias:from basic mechanisms to molecular therapeutics[J]. Ann Intern Med, 2003, 138: 819-830.
4Telegeev GD, Dubrovska AN, Dybkov MV, et al. Influence of BCR/ABL fusion proteins on the course of Ph leukemias [J]. ActaBioehim Pol, 2004, 51: 845-849.
5Mundhada S, Luthra R, Cano P. Association of HLA class I and class H genes with bcr-abl transcripts in leukemia patients with t (9.22)(q34;ql 1)[J]. BMC cancer, 2004, 4: 25.
6Laport GG, Alvarnas.JC, Palmer JM, et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneichematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated totalbody irradiation-etoposide regimen[J]. Blood, 2008, 112: 903-909.
7Schuhz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia:a children's oncology group study [J]. Clin Oncol, 2009, 27: 5175-5181.
8Schrappe M, Aric6 M, Harbott J, et al. Philadelphia chromosome- positive (Ph+) childhood acute lymphonblastic leukemia:good initial steroid reponse allows early prediction of a favorable treatment outcome[J]. Blood, 1998, 92: 2730-2741.
9Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years[J]. Blood, 2007, 109: 58-60.
10Mahon FX , R6a D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecularremission for at least 2 years:the prospective, muhicentre Stop Imatinib (STIM) triM[J]. Lancet Oncol, 2010, 11: 1029-1035.
